Updated results from the KATHERINE trial suggest that T-DM1 can improve OS when compared to trastuzumab in patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant therapy. T-DM1 can improve OS when compared to trastuzumab in patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant therapy.
Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy.
– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date –– Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study –– These data will be presented as an or.
Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.
<p>Research led by Queen Mary University of London’s Wolfson Institute of Population Health has found that hormone levels, measured through blood tests, are an important indicator of whether women will benefit from recently licensed medication for the prevention of breast cancer.</p>